Recent News

• 10.21.2025 - Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
• 09.29.2025 - Development of a dried blood spot assay for the detection of GM-CSF autoantibodies to aid in the diagnosis of autoimmune pulmonary alveolar proteinosis
• 09.29.2025 - Relationship Between Pulmonary Gas Transfer, Respiratory Health-related Quality of Life (HRQoL), Exercise Capacity, and Surfactant Burden in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
• 09.29.2025 - Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (PAP)
• 09.22.2025 - Pharmacokinetics and Pharmacodynamics of Inhaled Molgramostim in Healthy People
• 08.20.2025 - Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
• 05.18.2025 - Molgramostim Reduces Surfactant Background Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP): Results from the IMPALA-2 Phase 3 Clinical Trial
• 05.18.2025 - The Effects of Molgramostim on Respiratory Health-Related Quality of Life and Patient-Reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP)

Recent Filings

• 10.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 8-K Current report
• 06.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - EX-99.1 EX-99.1